FindTrial
Sign In

Hiberix™

BIOLOGICAL9 trials

Sponsors

GlaxoSmithKline, Merck Sharp & Dohme LLC

Conditions

Acellular PertussisDiphtheriaHaemophilus Influenzae Type bHepatitis BInfections, MeningococcalNeisseria MeningitidisPneumococcal InfectionsPneumococcal Vaccines

Phase 2

Immunogenicity, Safety & Reactogenicity of GSK Vaccine Tritanrix™-HepB/Hib2.5 Compared to GSK Vaccine Tritanrix™-HepB/Hiberix™
CompletedNCT01061541
GlaxoSmithKlineHaemophilus Influenzae Type b
Start: 2003-08-31End: 2004-08-31Updated: 2016-09-09

Phase 3

Immune Memory of DTPw-HBV/Hib Vaccine Following Primary Vaccination, Immuno & Reacto of a Booster Dose Given in Infants
CompletedNCT00169442
GlaxoSmithKlineDiphtheria, Haemophilus Influenzae Type b, Hepatitis B +2
Start: 2005-02-10End: 2006-03-10Updated: 2018-06-06
Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study
CompletedNCT00291343
GlaxoSmithKlineInfections, Meningococcal
Start: 2006-02-01End: 2007-03-15Updated: 2018-06-06
Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m in Primed Subjects
CompletedNCT00317109
GlaxoSmithKlineInfections, Meningococcal
Start: 2006-04-19End: 2007-05-17Updated: 2018-06-06
Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.
CompletedNCT00326118
GlaxoSmithKlineHaemophilus Influenzae Type b, Neisseria Meningitidis
Start: 2006-06-01End: 2007-11-06Updated: 2018-08-24
Immunogenicity and Safety of GSK Biologicals' Infanrix/Hib in Children
CompletedNCT00696423
GlaxoSmithKlineAcellular Pertussis, Diphtheria, Tetanus
Start: 2008-06-07End: 2008-07-26Updated: 2018-06-06
Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine
CompletedNCT01309646
GlaxoSmithKlineAcellular Pertussis, Diphtheria, Haemophilus Influenzae Type b +2
Start: 2011-03-04End: 2012-02-24Updated: 2019-11-27
A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)
CompletedNCT03620162
Merck Sharp & Dohme LLCPneumococcal Infections
Start: 2018-10-18End: 2020-12-14Updated: 2023-01-17
Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)
CompletedNCT03893448
Merck Sharp & Dohme LLCPneumococcal Infections, Pneumococcal Vaccines
Start: 2019-06-19End: 2021-05-24Updated: 2023-07-28

Related Papers

An indirect treatment comparison (ITC) and matching-adjusted indirect comparison (MAIC) between a 15-valent (V114) and a 20-valent (PCV20) pneumococcal conjugate vaccine among healthy infants
Expert Review of Vaccines2023-10-176 citations
A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED)
Vaccine2023-01-0141 citations
A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION).
2022-12-1312 citations
Immunogenicity and safety of a combined DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course in healthy Korean infants: phase III, randomized study
Human Vaccines & Immunotherapeutics2018-11-155 citations
Five-year Antibody Persistence and Safety After a Single Dose of Combined Haemophilus influenzae Type B Neisseria meningitidis Serogroup C-Tetanus Toxoid Conjugate Vaccine in Haemophilus influenzae Type B-primed Toddlers.
2015-12-013 citations
Three-year antibody persistence and safety after a single dose of combined haemophilus influenzae type b (Hib)-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in Hib-primed toddlers.
2013-02-015 citations